No black box warning on record for Bylvay

As of the latest FDA labeling reviewed, Bylvay (ODEVIXIBAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Bylvay medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatoxicity : Obtain baseline liver tests and monitor patients frequently for the first 6 to 8 months after starting therapy, and as clinically indicated thereafter during treatment. If liver test abnormalities or signs of clinical hepatitis occur, consider dose reduction or treatment interruption. For persistent or recurrent liver test abnormalities relative to baselin

No black box warning on record for Bylvay

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatoxicity : Obtain baseline liver tests and monitor patients frequently for the first 6 to 8 months after starting therapy, and as clinically indicated thereafter during treatment. If liver test abnormalities or signs of clinical hepatitis occur, consider dose reduction or treatment interruption. For persistent or recurrent liver test abnormalities relative to baselin

Bylvay Black Box Warning

No black box warning on record for Bylvay

Other warnings & precautions

Bylvay Black Box Warning

No black box warning on record for Bylvay

Other warnings & precautions